All Actavis articles
-
BusinessLilly wins chemotherapy patent appeal
Firm also settles with generic manufacturers of erectile dysfunction drug Cialis
-
BusinessIndia’s Intas bags UK and Irish generics
Teva sheds former Actavis business to satisfy competition requirements of its Allergan generics takeover
-
Business
Lilly loses UK patent challenge
Allergan’s cancer drug generics do not infringe patents, say UK courts
-
Business
Job cuts at Allergan and Transgene
Allergan is shedding 300 staff at former Actavis site in Iceland, while Transgene is closing its French manufacturing plant with loss of 120 jobs
-
Business
Actavis plan to thwart generics blocked
Company prevented from withdrawing original formulation of Alzheimer’s drug to force patients onto extended release version and extend patent exclusivity
-
-
BusinessActavis rescues Allergan with $66 billion deal
Deal ends takeover fight with Valeant – but Actavis must still be ‘fairly ruthless’ to justify the high price
-
Business
Actavis boosts antibiotics with Durata buyout
$820 million deal gives Actavis control of newly-approved intravenous antibiotic
-
Business
Generics giants jostle over pain drug
Mylan and Actavis contest Teva’s generic celecoxib exclusivity
-
Business
Generics triumph in anti-inflammatory patent battle
Pfizer settles deals to allow copycat celecoxib
-
BusinessMegamerger brings Actavis into R&D race
$25bn Forest Labs takeover will see generics giant take on patented products
-
BusinessGenerics give injectables a shot
A rash of recent acquisitions sees generics companies eager to enter speciality manufacturing market
-
Business
Ups and downs for erectile dysfunction drugs
First new drug in a decade approved in Europe as Viagra patent expires